These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 8039111)

  • 1. The effects of cyclosporine on the pharmacokinetics of doxorubicin in patients with small cell lung cancer.
    Rushing DA; Raber SR; Rodvold KA; Piscitelli SC; Plank GS; Tewksbury DA
    Cancer; 1994 Aug; 74(3):834-41. PubMed ID: 8039111
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics and pharmacodynamics of doxorubicin in patients with small cell lung cancer.
    Piscitelli SC; Rodvold KA; Rushing DA; Tewksbury DA
    Clin Pharmacol Ther; 1993 May; 53(5):555-61. PubMed ID: 8387903
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I and pharmacokinetic study of the multidrug resistance modulator dexverapamil with EPOCH chemotherapy.
    Wilson WH; Jamis-Dow C; Bryant G; Balis FM; Klecker RW; Bates SE; Chabner BA; Steinberg SM; Kohler DR; Wittes RE
    J Clin Oncol; 1995 Aug; 13(8):1985-94. PubMed ID: 7636539
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of doxorubicin administered i.v. as Myocet (TLC D-99; liposome-encapsulated doxorubicin citrate) compared with conventional doxorubicin when given in combination with cyclophosphamide in patients with metastatic breast cancer.
    Swenson CE; Bolcsak LE; Batist G; Guthrie TH; Tkaczuk KH; Boxenbaum H; Welles L; Chow SC; Bhamra R; Chaikin P
    Anticancer Drugs; 2003 Mar; 14(3):239-46. PubMed ID: 12634619
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of high-dose cyclosporine on etoposide pharmacodynamics in a trial to reverse P-glycoprotein (MDR1 gene) mediated drug resistance.
    Lum BL; Kaubisch S; Fisher GA; Brown BW; Sikic BI
    Cancer Chemother Pharmacol; 2000; 45(4):305-11. PubMed ID: 10755319
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I pharmacokinetic study of cyclosporin A combined with doxorubicin.
    Erlichman C; Moore M; Thiessen JJ; Kerr IG; Walker S; Goodman P; Bjarnason G; DeAngelis C; Bunting P
    Cancer Res; 1993 Oct; 53(20):4837-42. PubMed ID: 8402670
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I trial of doxorubicin with cyclosporine as a modulator of multidrug resistance.
    Bartlett NL; Lum BL; Fisher GA; Brophy NA; Ehsan MN; Halsey J; Sikic BI
    J Clin Oncol; 1994 Apr; 12(4):835-42. PubMed ID: 8151326
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Etoposide combined with cyclophosphamide plus vincristine compared with doxorubicin plus cyclophosphamide plus vincristine and with high-dose cyclophosphamide plus vincristine in the treatment of small-cell carcinoma of the lung: a randomized trial of the Bristol Lung Cancer Study Group.
    Hong WK; Nicaise C; Lawson R; Maroun JA; Comis R; Speer J; Luedke D; Hurtubise M; Lanzotti V; Goodlow J
    J Clin Oncol; 1989 Apr; 7(4):450-6. PubMed ID: 2538577
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alteration of etoposide pharmacokinetics and pharmacodynamics by cyclosporine in a phase I trial to modulate multidrug resistance.
    Lum BL; Kaubisch S; Yahanda AM; Adler KM; Jew L; Ehsan MN; Brophy NA; Halsey J; Gosland MP; Sikic BI
    J Clin Oncol; 1992 Oct; 10(10):1635-42. PubMed ID: 1403041
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Pharmacokinetic profile of high-dose doxorubicin administered during a 6 h intravenous infusion in breast cancer patients].
    Wihlm J; Limacher JM; Levêque D; Duclos B; Dufour P; Bergerat JP; Methlin G
    Bull Cancer; 1997 Jun; 84(6):603-8. PubMed ID: 9295863
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reversal of multidrug resistance by SDZ PSC 833, combined with VAD (vincristine, doxorubicin, dexamethasone) in refractory multiple myeloma. A phase I study.
    Sonneveld P; Marie JP; Huisman C; Vekhoff A; Schoester M; Faussat AM; van Kapel J; Groenewegen A; Charnick S; Zittoun R; Löwenberg B
    Leukemia; 1996 Nov; 10(11):1741-50. PubMed ID: 8892677
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The disposition of doxorubicin on repeated dosing.
    Rushing DA; Piscitelli SC; Rodvold KA; Tewksbury DA
    J Clin Pharmacol; 1993 Aug; 33(8):698-702. PubMed ID: 8408728
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized comparison of high-dose versus conventional-dose cyclophosphamide, doxorubicin, and vincristine for extensive-stage small-cell lung cancer: a phase III trial of the Southeastern Cancer Study Group.
    Johnson DH; Einhorn LH; Birch R; Vollmer R; Perez C; Krauss S; Omura G; Greco FA
    J Clin Oncol; 1987 Nov; 5(11):1731-8. PubMed ID: 2824707
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical trials of modulation of multidrug resistance. Pharmacokinetic and pharmacodynamic considerations.
    Lum BL; Fisher GA; Brophy NA; Yahanda AM; Adler KM; Kaubisch S; Halsey J; Sikic BI
    Cancer; 1993 Dec; 72(11 Suppl):3502-14. PubMed ID: 7902206
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pilot study of cyclophosphamide-doxorubicin-vincristine-cisplatin-etoposide hybrid chemotherapy in small cell lung cancer.
    Ohnoshi T; Hiraki S; Ueoka H; Kiura K; Kamei H; Horiguchi T; Kodani T; Maeda T; Tabata M; Shibayama T
    Cancer; 1993 Sep; 72(5):1597-601. PubMed ID: 8394202
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Doxorubicin clearance in the obese.
    Rodvold KA; Rushing DA; Tewksbury DA
    J Clin Oncol; 1988 Aug; 6(8):1321-7. PubMed ID: 3411343
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase I and pharmacologic study of the MDR converter GF120918 in combination with doxorubicin in patients with advanced solid tumors.
    Planting AS; Sonneveld P; van der Gaast A; Sparreboom A; van der Burg ME; Luyten GP; de Leeuw K; de Boer-Dennert M; Wissel PS; Jewell RC; Paul EM; Purvis NB; Verweij J
    Cancer Chemother Pharmacol; 2005 Jan; 55(1):91-9. PubMed ID: 15565444
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of limited small-cell lung cancer with etoposide and cisplatin alternating with vincristine, doxorubicin, and cyclophosphamide versus concurrent etoposide, vincristine, doxorubicin, and cyclophosphamide and chest radiotherapy: a Southwest Oncology Group Study.
    Goodman GE; Crowley JJ; Blasko JC; Livingston RB; Beck TM; Demattia MD; Bukowski RM
    J Clin Oncol; 1990 Jan; 8(1):39-47. PubMed ID: 2153194
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized study of initial versus late chest irradiation combined with chemotherapy in limited-stage small-cell lung cancer. Aarhus Lung Cancer Group.
    Work E; Nielsen OS; Bentzen SM; Fode K; Palshof T
    J Clin Oncol; 1997 Sep; 15(9):3030-7. PubMed ID: 9294465
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of amiodarone, cyclosporin A, and PSC 833 on the cytotoxicity of mitoxantrone, doxorubicin, and vincristine in non-P-glycoprotein human small cell lung cancer cell lines.
    van der Graaf WT; de Vries EG; Timmer-Bosscha H; Meersma GJ; Mesander G; Vellenga E; Mulder NH
    Cancer Res; 1994 Oct; 54(20):5368-73. PubMed ID: 7923167
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.